307 related articles for article (PubMed ID: 32035719)
1. Comparative review of imipenem/cilastatin versus meropenem.
Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
[TBL] [Abstract][Full Text] [Related]
4. The pharmacology of meropenem, a new carbapenem antibiotic.
Craig WA
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S266-75. PubMed ID: 9126702
[TBL] [Abstract][Full Text] [Related]
5. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
[TBL] [Abstract][Full Text] [Related]
6. Safety of imipenem/cilastatin in neurocritical care patients.
Hoffman J; Trimble J; Brophy GM
Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700
[TBL] [Abstract][Full Text] [Related]
7. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Tamma PD; Hsu AJ
J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
[TBL] [Abstract][Full Text] [Related]
8. Meropenem: a new carbapenem antimicrobial.
Pryka RD; Haig GM
Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
[TBL] [Abstract][Full Text] [Related]
9. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
10. Does nephrotoxicity develop less frequently when vancomycin is combined with imipenem-cilastatin than with meropenem? A comparative study.
Hakeam HA; AlAnazi L; Mansour R; AlFudail S; AlMarzouq F
Infect Dis (Lond); 2019 Aug; 51(8):578-584. PubMed ID: 31122098
[No Abstract] [Full Text] [Related]
11. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
13. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
[TBL] [Abstract][Full Text] [Related]
14. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
15. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
16. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
17. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
[TBL] [Abstract][Full Text] [Related]
19. Meropenem: a review of its use in patients in intensive care.
Hurst M; Lamb HM
Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
[TBL] [Abstract][Full Text] [Related]
20. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
Edwards JR
New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]